CVS Health Corp (CVS)

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Clover Health (NASDAQ:CLOV).

The ultimate long-term investing strategy is buying stocks and holding them forever.

Walgreens Boots Alliance shares slipped slightly on Tuesday as investors adjusted positions ahead of its planned private equity deal.

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

These low-risk stocks can provide you with reliable and steadily growing passive income.

The drug is soon to launch in Europe with a new name and a big potential market.

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Humana (NYSE:HUM).

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Elevance Health (NYSE:ELV) and its peers.

Michael Burry and Warren Buffett invested in UnitedHealth, signaling confidence in its sector and potential for earnings recovery by 2027.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Costco won't sell abortion pill mifepristone in U.S. stores due to low demand amid pressure from religious groups.

In a striking display of market intervention and strategic investment, two major corporate developments are sending ripples through the financial world. The U.S. government is reportedly considering an unprecedented ownership stake in struggling chipmaker Intel (NASDAQ: INTC), signaling a direct and significant move to bolster domestic semiconductor manufacturing. Simultaneously,

The financial markets are grappling with a perplexing economic puzzle as recent inflation data presents a contradictory picture. July 2025 saw the Producer Price Index (PPI) surge significantly, indicating rising wholesale costs for businesses, while the Consumer Price Index (CPI) remained relatively steady. This divergence has sent mixed signals to

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Looking back on health insurance providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Cigna (NYSE:CI) and its peers.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including AMN Healthcare Services (NYSE:AMN) and its peers.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Cencora (NYSE:COR) and the rest of the health insurance providers stocks fared in Q2.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Pediatrix Medical Group (NYSE:MD) and its peers.